Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition - PubMed (original) (raw)
. 2006 May 15;112(2):208-13.
doi: 10.1016/j.jconrel.2006.02.014. Epub 2006 Feb 28.
Affiliations
- PMID: 16574265
- DOI: 10.1016/j.jconrel.2006.02.014
Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition
Alf Lamprecht et al. J Control Release. 2006.
Abstract
In cancer treatment, efficient therapeutic strategies could be impeded by cellular mechanisms such as the multidrug resistance. Recently, drug-loaded nanoparticles have been reported to be useful, since they allow entering the cancer cell and act as an intracellular anti-cancer drug reservoir. A new approach is proposed here by the use of lipid nanocapsules (LNC) which were hypothesized to reverse multidrug resistance additionally by their P-glycoprotein (P-gp) inhibiting surfactant. LNC (mean diameter 25 to 100 nm) were loaded with etoposide, tested for the drug release and their efficiency to reduce cell growth in cell culture for C6, F98, and 9L glioma cell lines. Sustained etoposide release can be provided over a period of 1 week (t10%: 1.4+/-0.1h; t50%: 15.9+/-2.8h). The P-gp inhibiting activity in-vitro was found to be independent from the LNC size. In cell culture, an internalization of LNC was observed in all glioma cell types. Etoposide LNC showed a generally higher efficiency than the drug solution while blank LNC were found to be less inhibitory than the pure drug at equivalent concentrations (IC50: C6: etoposide: 25.2 microM; LNC: 2.6-8.9 microM, F98: etoposide: 46.5 microM; LNC: 1.4-14.7 microM, 9L: etoposide: 58.2 microM; LNC: 4.4-12.7 microM). This effect was found to be particle size dependent within a range of an 8- (C6) to 33-fold (F98) increased cytotoxicity for smallest particles. When cells were incubated with etoposide solution in the presence of blank LNC, a slight growth inhibition was observed, however, distinctly lower than the drug-trapping particles. Moreover, cell toxicity on astrocytes was similar for etoposide LNC and etoposide solution. The mechanism of action of etoposide LNC was proposed to be a cell uptake followed by a sustained drug release from the LNC in combination with an intracellular P-gp inhibition ensuring a higher anticancer drug concentration inside the cancer cells.
Comment in
- Nanocarriers for overcoming multidrug resistance in cancers.
Banerjee R. Banerjee R. Nanomedicine (Lond). 2006 Dec;1(4):481-5. doi: 10.2217/17435889.1.4.481. Nanomedicine (Lond). 2006. PMID: 17716150 No abstract available.
Similar articles
- Lipid nanocapsules for intracellular drug delivery of anticancer drugs.
Lacoeuille F, Garcion E, Benoit JP, Lamprecht A. Lacoeuille F, et al. J Nanosci Nanotechnol. 2007 Dec;7(12):4612-7. J Nanosci Nanotechnol. 2007. PMID: 18283853 - Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas.
Allard E, Passirani C, Garcion E, Pigeon P, Vessières A, Jaouen G, Benoit JP. Allard E, et al. J Control Release. 2008 Sep 10;130(2):146-53. doi: 10.1016/j.jconrel.2008.05.027. Epub 2008 Jun 5. J Control Release. 2008. PMID: 18582507 - Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel.
Hureaux J, Lagarce F, Gagnadoux F, Vecellio L, Clavreul A, Roger E, Kempf M, Racineux JL, Diot P, Benoit JP, Urban T. Hureaux J, et al. Eur J Pharm Biopharm. 2009 Oct;73(2):239-46. doi: 10.1016/j.ejpb.2009.06.013. Epub 2009 Jun 26. Eur J Pharm Biopharm. 2009. PMID: 19560538 - Tailoring nanocarriers for intracellular protein delivery.
Gu Z, Biswas A, Zhao M, Tang Y. Gu Z, et al. Chem Soc Rev. 2011 Jul;40(7):3638-55. doi: 10.1039/c0cs00227e. Epub 2011 May 12. Chem Soc Rev. 2011. PMID: 21566806 Review. - [Role of Scaffold Proteins in Functional Alteration of Small Intestinal P-glycoprotein by Anti-cancer Drugs].
Kobori T, Harada S, Nakamoto K, Tokuyama S. Kobori T, et al. Yakugaku Zasshi. 2015;135(5):687-95. doi: 10.1248/yakushi.14-00234-1. Yakugaku Zasshi. 2015. PMID: 25948303 Review. Japanese.
Cited by
- Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.
Yadav P, Ambudkar SV, Rajendra Prasad N. Yadav P, et al. J Nanobiotechnology. 2022 Sep 24;20(1):423. doi: 10.1186/s12951-022-01626-z. J Nanobiotechnology. 2022. PMID: 36153528 Free PMC article. Review. - Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.
Ramishetti S, Huang L. Ramishetti S, et al. Ther Deliv. 2012 Dec;3(12):1429-45. doi: 10.4155/tde.12.127. Ther Deliv. 2012. PMID: 23323560 Free PMC article. Review. - Lipid nanocapsule-based gels for enhancement of transdermal delivery of ketorolac tromethamine.
Varshosaz J, Hajhashemi V, Soltanzadeh S. Varshosaz J, et al. J Drug Deliv. 2011;2011:571272. doi: 10.1155/2011/571272. Epub 2011 Nov 17. J Drug Deliv. 2011. PMID: 22175029 Free PMC article. - Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.
Guo ZH, Khattak S, Rauf MA, Ansari MA, Alomary MN, Razak S, Yang CY, Wu DD, Ji XY. Guo ZH, et al. Molecules. 2023 Jan 28;28(3):1283. doi: 10.3390/molecules28031283. Molecules. 2023. PMID: 36770950 Free PMC article. Review. - Nanocarrier-mediated antioxidant delivery for liver diseases.
Li S, Li H, Xu X, Saw PE, Zhang L. Li S, et al. Theranostics. 2020 Jan 1;10(3):1262-1280. doi: 10.7150/thno.38834. eCollection 2020. Theranostics. 2020. PMID: 31938064 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous